口服氟喹诺酮与阿莫西林-克拉维酸暴露与周围神经病风险的关联
当前口服氟喹诺酮暴露与新发周围神经病相对发生率升高相关(调整后发生率比1.47,95%CI 1.13-1.92),而阿莫西林-克拉维酸未见显著风险升高。
要点
- 当前口服氟喹诺酮暴露与新发周围神经病风险升高相关,调整后发生率比1.47。
- 风险随当前暴露每增加1天约升高3%,且暴露后可持续至180天。
- 口服阿莫西林-克拉维酸暴露未见周围神经病风险显著升高。
核心结论
- 口服氟喹诺酮治疗与新发周围神经病风险升高相关,风险可能取决于暴露时机与累积剂量。
- 医务人员在开具氟喹诺酮抗生素时应考虑这一潜在风险。
研究设计与样本
- 数据分析于2018年1月8日进行,并做敏感性分析检验结果一致性。
主要发现
- 当前口服氟喹诺酮暴露与非暴露相比,新发周围神经病调整后发生率比为1.47(95%CI 1.13-1.92)。
- 当前氟喹诺酮暴露每增加1天,风险约升高3%,且暴露后风险持续至180天。
- 口服阿莫西林-克拉维酸暴露未见周围神经病风险显著升高。
- 当前口服氟喹诺酮暴露的绝对风险为每1万人年2.4(95%CI 1.8-3.1)。
关键数值与推荐
- NNH在男性和60岁以上患者中最大。
- 病例平均(SD)年龄65.6(14.7)岁,女性2809例(52.4%);对照平均(SD)年龄64.4(15.2)岁,女性9485例(54.9%)。
临床怎么用
- 开具口服氟喹诺酮时应权衡新发周围神经病的潜在风险,尤其关注男性及60岁以上患者。
- 应关注氟喹诺酮暴露时机与累积剂量对周围神经病风险的影响。
局限性
- 原文未报告基于电子病历记录诊断周围神经病可能存在的错分等具体局限说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. OBJECTIVE: To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure with peripheral neuropathy and to examine how risk may be affected by timing of fluoroquinolone exposure and by other risk factors. DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study used anonymized data from all patients routinely registered with general practices in The Health Improvement Network database, a large primary care population database in the United Kingdom, from January 1, 1999, to December 31, 2015. Data analyses were conducted January 8, 2018. The cohort consisted of 1 338 900 adults issued 1 or more prescriptions of fluoroquinolone (34.3%) or amoxicillin-clavulanate (65.7%) antibiotics. Adults with incident peripheral neuropathy were matched (on age, sex, general practice, and calendar time) with up to 4 controls by using incidence density sampling selected from a cohort prescribed oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Incidence rate ratios of peripheral neuropathy were calculated for fluoroquinolone and for amoxicillin-clavulanate exposure and compared with nonexposure among patients without diabetes, with sensitivity analyses testing the consistency of the results. Population mean-adjusted rate differences were then estimated, including the number needed to harm for various durations of fluoroquinolone therapy. EXPOSURES: Current and cumulative exposure to oral fluoroquinolone or amoxicillin-clavulanate antibiotics. MAIN OUTCOMES AND MEASURES: Incident peripheral neuropathy cases recorded in electronic medical records. RESULTS: In total, 5357 patients with incident peripheral neuropathy (mean [SD] age, 65.6 [14.7] years; 2809 women [52.4%]) were matched to 17 285 controls (mean [SD] age, 64.4 [15.2] years; 9485 women [54.9%]) without diabetes. Current oral fluoroquinolone exposure was associated with an increased relative incidence of peripheral neuropathy compared with nonexposure (adjusted incident rate ratio, 1.47; 95% CI, 1.13-1.92). Risk increased by approximately 3% for each additional day of current fluoroquinolone exposure and persisted for up to 180 days following exposure. No significant increased risk was observed with oral amoxicillin-clavulanate exposure. The absolute risk with current oral fluoroquinolone exposure was 2.4 (95% CI, 1.8-3.1) per 10 000 patients per year of current use. The number needed to harm for a 10-day course was 152 083 patients (95% CI, 117 742-202 778) and was greatest among men and among patients older than 60 years. CONCLUSIONS AND RELEVANCE: The results of the present study suggested that oral fluoroquinolone therapy was associated with an increased risk of incident peripheral neuropathy that may depend on the timing of the exposure and the cumulative dose. Health care professionals should consider these potential risks when prescribing fluoroquinolone antibiotics.
引用
- Morales D, Pacurariu A, Slattery J, et al. Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy. JAMA Neurol. 2019. PMID: 31034074. doi:10.1001/jamaneurol.2019.0887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。